Relapse rates in 29 diagnosis and disease stage groups
| Disease . | Disease stage . | Patients,N . | PY offollow-up* . | Relapse rateper PY . |
|---|---|---|---|---|
| Low risk | ||||
| CLL | CR | 7 | 8.2 | 0.00 |
| NHL, low grade | Not in CR | 34 | 40.8 | 0.15 |
| NHL, low grade | CR | 9 | 11.1 | 0.18 |
| Waldenström | Advanced | 9 | 10.8 | 0.19 |
| MM | CR† | 29 | 42.8 | 0.19 |
| NHL, mantle cell | CR | 16 | 15.7 | 0.19 |
| NHL, mantle cell | Not in CR | 25 | 30.4 | 0.20 |
| MPD | Advanced | 19 | 18.6 | 0.21 |
| NHL, high grade | CR | 26 | 31.0 | 0.23 |
| ALL | 1st CR | 19 | 21.0 | 0.24 |
| Standard risk | ||||
| CLL | Not in CR | 75 | 89.0 | 0.26 |
| MM | Not in CR | 136 | 174.8 | 0.27 |
| MDS | RA/RARS | 20 | 18.2 | 0.33 |
| AML | 1st CR | 80 | 78.3 | 0.33 |
| CML | 1st CP | 26 | 32.8 | 0.34 |
| AML | ≥2nd CR | 59 | 62.6 | 0.37 |
| High risk | ||||
| MDS | RAEB/RAEB-t | 23 | 19.2 | 0.52 |
| AML | Evolved from MDS | 42 | 29.1 | 0.55 |
| NHL, high grade | Not in CR | 36 | 26.3 | 0.57 |
| HD | CR | 13 | 9.6 | 0.62 |
| MDS | Secondary | 18 | 14.4 | 0.70 |
| HD | Not in CR | 38 | 30.6 | 0.72 |
| AML | Not in CR | 13 | 9.2 | 0.87 |
| CML | AP/BC | 14 | 10.1 | 0.99 |
| CML | 2nd CP | 7 | 3.8 | 1.05 |
| Renal cell | Metastatic | 18 | 10.6 | 1.23 |
| ALL | ≥2nd CR | 8 | 4.6 | 1.29 |
| ALL | Not in CR | 3 | 2.2 | 1.35 |
| CMML | Advanced | 12 | 6.3 | 1.42 |
| Disease . | Disease stage . | Patients,N . | PY offollow-up* . | Relapse rateper PY . |
|---|---|---|---|---|
| Low risk | ||||
| CLL | CR | 7 | 8.2 | 0.00 |
| NHL, low grade | Not in CR | 34 | 40.8 | 0.15 |
| NHL, low grade | CR | 9 | 11.1 | 0.18 |
| Waldenström | Advanced | 9 | 10.8 | 0.19 |
| MM | CR† | 29 | 42.8 | 0.19 |
| NHL, mantle cell | CR | 16 | 15.7 | 0.19 |
| NHL, mantle cell | Not in CR | 25 | 30.4 | 0.20 |
| MPD | Advanced | 19 | 18.6 | 0.21 |
| NHL, high grade | CR | 26 | 31.0 | 0.23 |
| ALL | 1st CR | 19 | 21.0 | 0.24 |
| Standard risk | ||||
| CLL | Not in CR | 75 | 89.0 | 0.26 |
| MM | Not in CR | 136 | 174.8 | 0.27 |
| MDS | RA/RARS | 20 | 18.2 | 0.33 |
| AML | 1st CR | 80 | 78.3 | 0.33 |
| CML | 1st CP | 26 | 32.8 | 0.34 |
| AML | ≥2nd CR | 59 | 62.6 | 0.37 |
| High risk | ||||
| MDS | RAEB/RAEB-t | 23 | 19.2 | 0.52 |
| AML | Evolved from MDS | 42 | 29.1 | 0.55 |
| NHL, high grade | Not in CR | 36 | 26.3 | 0.57 |
| HD | CR | 13 | 9.6 | 0.62 |
| MDS | Secondary | 18 | 14.4 | 0.70 |
| HD | Not in CR | 38 | 30.6 | 0.72 |
| AML | Not in CR | 13 | 9.2 | 0.87 |
| CML | AP/BC | 14 | 10.1 | 0.99 |
| CML | 2nd CP | 7 | 3.8 | 1.05 |
| Renal cell | Metastatic | 18 | 10.6 | 1.23 |
| ALL | ≥2nd CR | 8 | 4.6 | 1.29 |
| ALL | Not in CR | 3 | 2.2 | 1.35 |
| CMML | Advanced | 12 | 6.3 | 1.42 |
CLL indicates chronic lymphocytic leukemia; MM, multiple myeloma; NHL, non-Hodgkin lymphoma; CR, complete remission; MPD, myeloproliferative disease; ALL, acute lymphoblastic leukemia; MDS, myelodysplastic syndrome; RA, refractory anemia; RARS, refractory anemia with ringed sideroblasts; AML, acute myeloid leukemia; CML, chronic myeloid leukemia; CP, chronic phase; RAEB, refractory anemia with excess blasts; RAEB-t, refractory anemia with excess blasts in transformation; HD, Hodgkin disease; AP, accelerated phase; BC, blast crisis; CMML, chronic myelomonocytic leukemia.
PY of follow-up is the total person-years of observation time from transplant until death, relapse/progression, last contact, or 2 years.
The criteria for complete remission from MM were absence of monoclonal immunoglobulin and of discernible light chains in urine by standard electrophoresis, the absence of visible monoclonal bands on immunofixation, <1% plasma cells in marrow aspirates, the absence of evidence of clonal disease according to flow cytometry of marrow cells, and the absence of an increase in the size or number of osteolytic lesions.